BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Leqvio (Inclisiran) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Leqvio (Inclisiran)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06501443-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20261127
DTEND;VALUE=DATE:20261128
SUMMARY:Leqvio (Inclisiran): Phase 4 readout est. (NCT06501443)
DESCRIPTION:Leqvio (Inclisiran)\, phase 4\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: LATAM LOWERS LDL-C\nEstimated primary completion: 27 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisiran
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 01443
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07626281-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20261221
DTEND;VALUE=DATE:20261222
SUMMARY:Leqvio (Inclisiran): Phase 1 readout est. (NCT07626281)
DESCRIPTION:Leqvio (Inclisiran)\, phase 1.\nStudy: Assessment of Safety\, T
 olerability\, Pharmacokinetics and Pharmacodynamics of a New Formulation o
 f Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed 
 Formulation\nEstimated primary completion: 21 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/inclisiran#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07626281
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06372925-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Leqvio (Inclisiran): Phase 4 readout est. (NCT06372925)
DESCRIPTION:Leqvio (Inclisiran)\, phase 4.\nStudy: Intravascular Imaging St
 udy of the Effect of Inclisiran on Plaque in Patients With Acute Myocardia
 l Infarction\nEstimated primary completion: 30 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/inclisiran#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06372925
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06249165-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Leqvio (Inclisiran): Phase 4 readout est. (NCT06249165)
DESCRIPTION:Leqvio (Inclisiran)\, phase 4\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: VictORION-INCLUSION: Evaluating Inclisiran for Cholestero
 l Managment in Heart Disease\nEstimated primary completion: 31 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/inclisiran#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06249165
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102628-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT07102628)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Evaluation of Efficacy and Safety of Early in Hospital In
 itiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
 \nEstimated primary completion: 16 January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07102628
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941792-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Leqvio (Inclisiran): Phase 4 readout est. (NCT06941792)
DESCRIPTION:Leqvio (Inclisiran)\, phase 4\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Inclisiran Effectiveness in China: a Pragmatic Randomized
  Trial\nEstimated primary completion: 30 April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06941792
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581808-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Leqvio (Inclisiran): Phase 4 readout est. (NCT07581808)
DESCRIPTION:Leqvio (Inclisiran)\, phase 4\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in S
 econdary Prevention\nEstimated primary completion: May 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/inclisiran#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07581808
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05030428-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05030428)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study of Inclisiran to Prevent Cardiovascular (CV) Events
  in Participants With Established Cardiovascular Disease\nEstimated primar
 y completion: 10 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/inclisiran#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05030428
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07884955-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Leqvio (Inclisiran): Phase na readout est. (NCT07884955)
DESCRIPTION:Leqvio (Inclisiran)\, phase na.\nStudy: Comparing Inclisiran Ve
 rsus Statin for Primary Aldosteronism\nEstimated primary completion: 1 Aug
 ust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisiran#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0788
 4955
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803822-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Leqvio (Inclisiran): Phase 2 readout est. (NCT07803822)
DESCRIPTION:Leqvio (Inclisiran)\, phase 2\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Phase 2 Clinical Study of MWX203 Injection Alone or in Co
 mbination With Inclisiran Sodium Injection in Patients With Mixed Dyslipid
 emia\nEstimated primary completion: February 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07803822
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813911-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20280203
DTEND;VALUE=DATE:20280204
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06813911)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Backgrou
 nd Inclisiran in Participants With Elevated Lp(a) and Established ASCVD\nE
 stimated primary completion: 3 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06813911
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684469-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Leqvio (Inclisiran): Phase 4 readout est. (NCT07684469)
DESCRIPTION:Leqvio (Inclisiran)\, phase 4\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Comparative Assessment of Inclisiran on Top of Standard o
 f Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronar
 y Syndrome Patients in Saudi Arabia\nEstimated primary completion: 29 Febr
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisiran
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 84469
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06597019-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06597019)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study to Evaluate Efficacy and Safety of Inclisiran in Ch
 ildren With Heterozygous Familial Hypercholesterolemia\nEstimated primary 
 completion: 21 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/inclisiran#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06597019
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06597006-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06597006)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study to Evaluate Safety\, Tolerability and Efficacy of I
 nclisiran in Children With Homozygous Familial Hypercholesterolemia\nEstim
 ated primary completion: 21 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06597006
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865885-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Leqvio (Inclisiran): Phase 4 readout est. (NCT06865885)
DESCRIPTION:Leqvio (Inclisiran)\, phase 4\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: LDL-C Optimization Using Inclisiran in Patients in Which 
 Drug-Drug Interactions Limit LDL Lowering\nEstimated primary completion: 1
  June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisira
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 865885
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05739383-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20290416
DTEND;VALUE=DATE:20290417
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05739383)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: A Study of Inclisiran to Prevent Cardiovascular Events in
  High-risk Primary Prevention Patients.\nEstimated primary completion: 16 
 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisira
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 739383
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799779-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Leqvio (Inclisiran): Phase 4 readout est. (NCT07799779)
DESCRIPTION:Leqvio (Inclisiran)\, phase 4\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Early Intensive Lipid-Lowering With Inclisiran for Plaque
  Stabilization in Acute Coronary Syndrome\nEstimated primary completion: S
 eptember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclis
 iran#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07799779
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909565-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Leqvio (Inclisiran): Phase 4 readout est. (NCT06909565)
DESCRIPTION:Leqvio (Inclisiran)\, phase 4.\nStudy: Inclisiran Versus Placeb
 o for the Prevention of Major Adverse Cardiovascular and Limb Events in Pa
 tients Undergoing Percutaneous Coronary Intervention or Peripheral Endovas
 cular Intervention\nEstimated primary completion: October 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/inclisiran#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06909565
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05682378-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20320325
DTEND;VALUE=DATE:20320326
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05682378)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Long-term Safety and Tolerability of Inclisiran in Partic
 ipants With HeFH or HoFH Who Have Completed the Pediatric ORION-16\, ORION
 -13\, ORION-20\, or ORION-19 Studies\nEstimated primary completion: 25 Mar
 ch 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisiran#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05682
 378
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06494501-1034@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06494501)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: The Prevent Coronary Artery Disease Trial\nEstimated prim
 ary completion: 30 June 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/inclisiran#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06494501
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
